Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DENTSPLY SIRONA Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,943 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Purchase · Acquired 15,175 · Balance 55,943 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.87 to 9.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.87 to 9.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalent, Inc.
Report date December 18, 2024 · Filed December 18, 2024
Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 1
1 source rowRow 1 · 2024-12-18 · Disposition to issuer · Disposed 18,052 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: Includes restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Disposition to issuer · Disposed 7,738 · Balance 5,398 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Row 2 · 2026-03-23 · Disposition to issuer · Disposed 5,398 · Balance 0 F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-23 · Disposition to issuer · Disposed 7,422 · Balance 0 F3: Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy (each a "DSU"). Each DSU represents a contingent right to receive one share of Exact Sciences Corporation common stock. F4: At the Effective Time, each DSU outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such DSU, less any applicable tax withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
F3: Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy (each a "DSU"). Each DSU represents a contingent right to receive one share of Exact Sciences Corporation common stock.
F4: At the Effective Time, each DSU outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such DSU, less any applicable tax withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:59 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | PurchaseCommon Stock | 15,175 | $9.89 | $150,004.88 |
DisclosureSEC source: 0000818479-26-000208 · form4.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,943 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.87 to 9.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:28 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 22,822 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-26-000183 · form4.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,768 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerDeferred Stock Units · Derivative | 7,422 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118742 · ownership.xml · derivative · entry 3 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,422 shares Expires not disclosed F3 · security: Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy (each a "DSU"). Each DSU represents a contingent right to receive one share of Exact Sciences Corporation common stock. F4 · shares: At the Effective Time, each DSU outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such DSU, less any applicable tax withholding. F4 · derivative.exercise_date: At the Effective Time, each DSU outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such DSU, less any applicable tax withholding. F4 · derivative.expiration_date: At the Effective Time, each DSU outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such DSU, less any applicable tax withholding. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 5,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118742 · ownership.xml · nonDerivative · entry 2 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 7,738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118742 · ownership.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,398 F1 · price: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:04 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 245.816 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-26-000026 · form4.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,944.987 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| October 10, 2025 Filed Oct 15, 2025 20:26 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 223.681 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-25-000204 · form4.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,699.171 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:32 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 210.49 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-25-000119 · form4.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,475.49 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086890 · ownership.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,136 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:17 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 13,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015706 · form4.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,265 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:57 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 3,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006936 · form4.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,385 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| December 18, 2024 Filed Dec 18, 2024 12:52 UTC | Catalent, Inc. CTLT · Entity 16279 | Disposition to issuerCommon Stock | 18,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-137701 · ownership.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2 · shares: Includes restricted stock units ("RSUs"). F3 · price: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4 · price: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 17:11 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 4,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-24-000105 · wk-form4_1730495467.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,052 F1 · shares: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of (i) a "change in control" (as defined in the Catalent, Inc. 2018 Omnibus Incentive Plan) and (ii) one year from the date of award, subject to continued service. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantDeferred Stock Units · Derivative | 7,422 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074408 · ownership.xml · derivative · entry 2 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,422 Underlying: Common Stock · 7,422 shares Expires not disclosed F2 · security: Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy. Each deferred stock unit represents a contingent right to receive one share of Exact Sciences Corporation common stock. F3 · derivative.exercise_date: These deferred stock units vest in three equal annual installments beginning on June 13, 2025. F3 · derivative.expiration_date: These deferred stock units vest in three equal annual installments beginning on June 13, 2025. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074408 · ownership.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 13, 2024 Filed Dec 20, 2024 16:30 UTC Amendment | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,939 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139092 · ownership.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,939 F1 · shares: On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 5,444 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 17:06 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 6,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-23-000161 · wk-form4_1698786362.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,389 F1 · shares: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 16:37 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 4,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-22-000161 · wf-form4_166724863929581.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,396 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2023 annual meeting of shareholders. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 07:59 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000168 · wf-form4_163576795067271.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,247 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2022 annual meeting of shareholders. F2 · balance_after: Includes restricted stock units. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:09 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 845 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000053 · wf-form4_161982773892303.xml · nonDerivative · entry 1 Barber Michael J · CIK 0001859849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units (pro-rated to reflect a partial year of service) provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.